Migraine and estrogen by Chai, Nu Cindy et al.
Migraine and estrogen
Nu Cindy Chaia, B. Lee Peterlina, and Anne H. Calhounb
aDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland
bCarolina Headache Institute, University of North Carolina, Chapel Hill, North Carolina, USA
Abstract
Purpose of review—The aim is to systematically and critically review the relationship between
migraine and estrogen, the predominant female sex hormone, with a focus on studies published in
the last 18 months.
Recent findings—Recent functional MRI (fMRI) studies of the brain support the existence of
anatomical and functional differences between men and women, as well as between participants
with migraine and healthy controls. In addition to the naturally occurring changes in endogenous
sex hormones over the lifespan (e.g. puberty and menopause), exogenous sex hormones (e.g.
hormonal contraception or hormone therapy) also may modulate migraine. Recent data support the
historical view of an elevated risk of migraine with significant drops in estrogen levels. In
addition, several lines of research support that reducing the magnitude of decline in estrogen
concentrations prevents menstrually related migraine (MRM) and migraine aura frequency.
Summary—Current literature has consistently demonstrated that headache, in particular
migraine, is more prevalent in women as compared with men, specifically during reproductive
years. Recent studies have found differences in headache characteristics, central nervous system
anatomy, as well as functional activation by fMRI between the sexes in migraine patients.
Although the cause underlying these differences is likely multifactorial, considerable evidence
supports an important role for sex hormones. Recent studies continue to support that MRM is
precipitated by drops in estrogen concentrations, and minimizing this decline may prevent these
headaches. Limited data also suggest that specific regimens of combined hormone contraceptive
use in MRM and migraine with aura may decrease both headache frequency and aura.
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Substantial research has emerged in the recent years highlighting sex differences in the
epidemiology and characteristics of various headache disorders, specifically in migraine.
The cause underlying these sex differences is likely multifactorial, involving both biological
and psychosocial factors. Of the many biological factors, sex hormones are likely a major
contributor. In addition to differences between men and women, migraine prevalence rates
and characteristics vary in women by hormonal status (i.e. across the menstrual cycle, with
or without taking hormonal contraceptives), further underscoring a strong role for sex
hormones in headache.
Although the association between migraine and sex hormones has been repeatedly
demonstrated, the exact pathophysiology of this association has not yet been fully
elucidated. Further, for many clinicians, the effect of various hormonal contraceptive agents
on migraine, specifically migraine with aura (MwA) continues to be a source of confusion.
In this review, we first briefly discuss the most recent epidemiologic data evaluating sex
differences in migraine. We then systematically and critically review the available clinical
and experimental studies published in the last 18 months examining the role of estrogen, the
predominant female sex hormone, in migraine. We close with a brief discussion on future
directions necessary to further elucidate the role of estrogen and sex hormones in migraine.
SEARCH METHOD
A systematic search of the PubMed database was conducted using keywords ‘estrogen’,
‘estradiol’, ‘estrone’ or ‘sex hormone’ and ‘headache’, ‘pain’ or ‘migraine’. In addition,
reference lists of relevant articles were reviewed for inclusion. General population studies
(cross-sectional and longitudinal), clinic-based case series, human clinical trials as well as
animal studies evaluating the association between estrogen and migraine were included.
Studies evaluating the effect of sex hormones on pain in general, headache in general or
other headache subtypes were excluded. Only studies published between April 2012 and
October 2013 were included for discussion in this article.
SEX DIFFERENCES IN HEADACHE: EPIDEMIOLOGIC STUDIES
An expansive, world-wide, body of literature has consistently demonstrated that headache,
and in particular migraine, is more prevalent in women as compared with men [1–3]. Most
recently, Buse et al. [4] analyzed data from over 160 000 participants, 12 years of age or
older, in the American Migraine Prevalence and Prevention study and again substantiated
the previously reported higher prevalence of migraine in women as compared with men at
all ages. The female to male ratio peaked at 3.25 among those between 18 and 29 years of
age [probability ratio 3.25; 95% confidence interval (CI): 3.00, 3.53]. Similarly, probable
migraine was also found to be more prevalent in women (peaking at ages 18–29, probability
ratio 1.53, 95% CI =1.35–1.73) as compared with men. As previously described [1], this
female predominance was consistent across racial groups [4]. Further, this study reported
that although men and women reported similar headache severity and frequency, women
reported more migraine-related symptoms (i.e. photophobia, nausea, etc) and more
migraine-related disability [4].
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SEX DIFFERENCES IN HEADACHE: IMAGING STUDIES
In addition to epidemiologic evidence of sex differences in migraine, brain MRI studies
support both structural and functional sex differences in those with migraine [5▪].
Specifically, Maleki et al. [5▪] used high-field MRI to compare age-matched male and
female migraineurs to healthy controls. Female migraineurs were found to have thicker
posterior insula and precuneus cortices as compared with both male migraineurs and healthy
controls of both sexes. However, no difference in cortical thickness was found between male
migraineurs and male healthy controls. Furthermore, using functional MRI (fMRI), noxious
thermal stimulation produced stronger responses in areas such as the amygdala and
parahippocampus, in female as compared with male participants with migraine.
Maleki et al.’s study is of particular interest as the anatomical difference found in the female
migraineur is contributable neither to the female sex alone nor the migraine disease state
alone (as it was compared with both female healthy controls and male participants with
migraine). Therefore, one can theorize that a combination of being female and having
migraine may lead to changes in brain anatomy and sensory responsiveness and result in
differences in migraine characteristics, (as seen in epidemiological studies). However, as
Maleki’s study cannot determine the directionality of the association between the anatomical
difference among the sexes and the migraine disease state, it is also possible that those with
a specific anatomical variant (i.e. thicker posterior insular and precuneus cortices) together
with being of the female sex (and encompassing female-specific levels and ratios of sex
hormones) can account for an increased risk of developing migraine.
SEX HORMONE’S CONTRIBUTION IN MIGRAINE
The above data suggest that although both men and women may suffer from migraine, ‘male
migraine’ and ‘female migraine’ differ in characteristics because of their difference in sex,
which is most obviously marked by sex hormone differences. In addition, the higher
migraine prevalence among women of reproductive age, and the lower migraine prevalence
among those prior to puberty and postmenopausal may also be, at least in part, explained by
their different sex hormone status.
Overall, research in the area of sex hormone and headache is active and diverse, including
both animal and human studies. Estrogen, a predominant female sex hormone, is of
particular interest. In the next section, we briefly discuss the role of estrogen in the central
nervous system (CNS), and critically review the most recent studies evaluating its
implication in migraine.
ESTROGEN AND THE CENTRAL NERVOUS SYSTEM
In nonpregnant women, estrogens are produced primarily by the ovaries, and in smaller
quantities by adipocytes, the liver, adrenal glands and breasts. In men, estrogen is
synthesized from its precursors, androstenedione and testosterone, by aromatization.
Although estrogen quantities are much lower in men than in young women, they are
relatively stable in men and undergo a much more gradual decline with age as compared
with women — to the extent that men over the age of 60 have approximately three times
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more circulating estradiol than postmenopausal women who are not taking exogenous
estrogen [6]. In addition to reproduction, accumulating data support that estrogen
participates in multiple physiological and pathological processes in both sexes, including
homeostasis, memory and pain processing [7–9].
In nonpregnant women, the three major estrogens are estradiol (E2), estrone and estriol, with
estradiol being the most potent form [10]. Estrogen’s effect on the brain can occur via at
least three distinct pathways: direct diffusion of peripheral estrogen into the CNS,
conversion of testosterone and androstenedione in the brain by aromatases in the presynaptic
terminals in the brain [11] or de-novo synthesis of estrogen in the brain from cholesterol
[12]. In the brain, estrogen can exert its effect by binding to estrogen receptors, usually
located in the nucleus or cytoplasm, with subsequent gene transcription and protein
synthesis; or alternatively estrogen can act by nongenomic mechanisms [13]. Recent data
suggest that the transcriptional activity of human brain estrogen receptors is cell-type
specific [14].
ANIMAL STUDIES
Many limitations exist in animal studies evaluating migraine. First, the majority of studies
use predominantly male animals, which may not be representative of a predominantly
female disorder [15,16]. Secondly, despite a variety of different migraine animal models,
none are able to fully model the complexities of the various pain and pain-related symptoms
of migraine. Finally, most animal models of migraine have been formed based on our
current understanding of migraine pathophysiology, and rely less on the nociceptive
behavior of the animals to corroborate that headache was the result of the interventions [17].
With these limitations in mind, two studies using two different rodent models of migraine
were recently published and are reviewed below (see Table 1) [18,19].
Using the nitroglycerin (NTG)-induced neuronal activation (as detected by fos activation)
rodent migraine model, Greco et al. [18] attempted to evaluate the influence of estrogen on
migraine in rats. Intact females were tested during the proestrus phase of the estrus cycle
(generally corresponding to a period of estrogen peak, see Fig. 1a) [20], and were
demonstrated to have an increased NTG-induced activation in the paraventricular nucleus
and supraoptic nucleus of the hypothalamus, as well as the nucleus trigeminalis caudalis of
the brainstem as compared with intact male rats. Further, although ovariectomy significantly
reduced neuronal activation in all above-mentioned areas in the female rat, chronic
intraperitoneal administration of estrogen restored the activation levels to those of an intact
female [18]. In contrast, in male gonadectomized rats, neuronal suppression was
demonstrated only in the nucleus trigeminalis caudalis as compared with intact males.
In a second study, using the migraine rodent model of meningeal inflammation as measured
by dural mast cell activation, Boes and Levy [19] demonstrated that dural mast cell
activation in intact female rats was consistently higher than in intact males, with the
exception of the proestrus phase (i.e. peak estrogen levels). In addition, overall mast cell
density was higher in estrus (a period of somewhat lower estrogen concentrations, see Fig.
1a) (P <0.01) and even higher in diestrus 1 (when estrogen concentrations are low) (P
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<0.01) as compared with the proestrus (peak estrogen) or the diestrus 2 (rising estrogen)
phases. Further, although ovariectomized females had decreased mast cell density, those
ovariectomized females that received a subsequent subcutaneous injection of E2 showed an
increase in dural mast cell density compared with those treated with placebo. Interestingly,
administration of progesterone together with E2 blunted the increase in dural mast cell
density seen after E2 treatment alone. Boes and Levy [19] also reported that the effect of E2
on mast cell density was time-specific – being apparent at 24 and 48 h after E2 injection and
disappearing after 72 h.
The above studies appear to report contradictory findings. Greco et al. [18] demonstrated
elevated pain sensitivity in females (increased NTG-induced fos activation) corresponding
to the proestrus phase, whereas Boes and Levy [19] showed a relatively lower state of pain-
sensitivity (decreased mast cell activation) in proestrus. Further, even though Boes and Levy
showed a lower pain response during a phase of high estrogen (proestrus) in normal cycling
rats, they showed an increased pain response when subcutaneous estrogen was given to
animals of a low estrogen state (ovariectomized rats). These conflicting data may be largely
because of the difficulty in determining the specific hormonal levels in rats (Fig. 1a).
Notably, neither study directly evaluated the status of sex hormones in the animals (i.e.
obtaining serum estrogen levels), but instead determined the estrus cycle based on vaginal
smears, a method extremely variable depending on the specific timing of the studies (Fig. 1).
These studies also demonstrate the difficulty in extrapolating the results of animal studies to
humans, as rats have brief 4-day estrus cycles in which a difference of a few hours can
produce either peak or trough estrogen concentrations (Fig. 1).
In addition to estrogen itself, different estrogen receptors have been studied recently in
animal models of general pain, although not specifically in headache or migraine [21–23].
As the differential effect of estrogen may very well be receptor-specific, further studies on
estrogen receptors in the headache or migraine rodent models would be of interest.
HUMAN STUDIES
Most human studies evaluating the effect of sex hormones on migraine have employed
either the documentation of life events marked by endogenous hormonal changes (e.g.
menstruation and menopause) or exogenous hormone use [e.g. contraceptive medication and
hormone replacement therapy (HRT)] to simulate a controlled hormonal state (Table 2)
[24,25,26▪▪]. One of the most significant limitations to these studies is the inability to truly
control each participant’s hormonal state. Specifically, the effect of hormonal contraceptives
on the total hormone level is significantly different depending on the pharmacology and the
‘architecture’ of the contraceptive administered, as well as whether ovulation was
successfully inhibited. Most combined hormonal contraceptives (CHCs) allow for a drop in
ethinyl estradiol concentration during a placebo week that ranges from 20 to 50 μg, levels
sufficient to trigger an estrogen withdrawal migraine. Only two regimens limit this drop to
10–15 μg, and would, therefore, not be expected to trigger menstrually related migraine
(MRM) [27]. Further, although CHCs almost always result in higher estrogen concentrations
than the native menstrual cycle, if ovulation is inhibited with one of the very few ultra-low
dose CHCs the resulting estrogen concentration can actually be lower than that of the native
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menstrual cycle. Thus, it is important for clinicians examining the available data to be
mindful of the type and dose of hormone therapy in order to draw appropriate conclusions.
Additionally, the relationship between different sex hormones (i.e. estrogens, progestogens
and testosterone) is complex and should be taken into consideration as a whole, in order to
properly evaluate the role of sex hormones in headache. And finally, most studies evaluate
only a small number of individuals, limiting our ability to draw firm conclusions.
Studies with a focus on changes in endogenous sex hormones
One recent cross-sectional survey evaluated the effect of endogenous hormonal changes in
women with migraine vs. tension-type headache (TTH). In this study, Karli et al. [28]
conducted a general population observational study evaluating 1333 women aged 18–65.
Participants responded to questions regarding menstruation, pregnancy, oral contraception
intake, as well as menopause and their impact on headache. Those with migraine were found
to be almost three-fold more likely to experience headache during menstruation than those
with TTH (odds ratio 2.79; 95% CI: 1.33–5.85, P =0.006) [28]. Additionally, although
previous data suggested a protective effect of pregnancy, in particular during the third
trimester, for those women with migraine [29], pregnancy did not appear to affect migraine
or TTH characteristics in any specific trend in this study. In addition, although the type and
dose of oral contraceptives used was not reported (a methodological limitation which
severely limits the conclusions that may be drawn from this aspect of the study) oral
contraceptive use was reported to be more likely to worsen migraine compared with TTH
(39 vs. 3.6%, P <0.001). Finally, more participants with migraine than those with TTH had
improvement in their headache during menopause (15.8 vs. 2.4%, P =0.046) [28].
In summary, although this study provides few new clues to the hormonal differences in
different headache conditions, it substantiates and highlights that participants with migraine
have a higher sensitivity to varying hormonal levels as compared with those with TTH.
Further, menopause, a life event marked by stable ovarian estrogen production (although
very low), generally corresponds to improvement in migraine.
Studies with a focus on the effect of exogenous sex hormones
Exogenous sex hormones (e.g. combined contraceptives) can also affect headache.
Specifically, estrogen administration in male-to-female transsexuals has been linked to the
development and worsening of headache [30] (Dr Thomas N. Ward, personal
communication). Further, abrupt drops in estrogen have long been suspected as a migraine
trigger [31]. On the basis of the observation of the existence of headache with estrogen
withdrawal, two recent studies evaluated the effect of estradiol valerate/dienogest (E2V/
DNG) on headache [24,25]. (Note: E2V/DNG is a tetraphasic — 2/5/17/2/2 regimen —
combination oral contraceptive administered in an estrogen step-down and progestin step-up
regimen. Each decline in estrogen is limited to 1 mg E2V, a decline equal to that originally
proposed by Calhoun [27] to prevent MRM.)
Both studies demonstrated a reduction in headache frequency and headache-medication
usage in participants using E2V/DNG [24,25] (see Table 2). Specifically, in a multicenter,
randomized, double-blinded study, Macias et al. [24] evaluated 223 women aged 18–50 who
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received E2V/DNG for six cycles, while a control group of 218 women received a
traditional 21/7 regimen of ethinyl estradiol/levonorgestrel (ethinyl estradiol 20 μg/LNG 100
μg). E2 V/DNG reduced the frequency and intensity of headache from baseline when
evaluated at cycle six (change from baseline: 47.7 ±29.4 mm) [24]. E2 V/DNG was also
associated with a greater mean reduction in the use of rescue medication on days 22–28,
compared with ethinyl estradiol/LNG by cycle six (number of ibuprofen 200 mg tablets: 3.5
±6.3 vs. 1.8 ±6.0 tablets; 95% CI: 3.04–0.48; P <0.05) [24]. Interestingly, investigators
reported that to a lesser degree, those randomized to the ethinyl estradiol 20 μg/LNG 100 μg
regimen also improved in their headache intensity at the end of the study from baseline (34.5
±25.7 mm). This would be expected if the participants at baseline were taking a combined
oral contraceptive (COC) with ethinyl estradiol dose greater than 20 μg, as the decline in
estrogen concentration on those pills would be 25–50 μg, greater than the 20 μg decline with
the study drug. However, as the investigators did not report baseline COC estrogen doses,
this cannot be accurately measured.
In a second prospective clinic-based study, 32 women older than 35 years of age with the
diagnosis of MRM were included [25]. The number of migraine attacks, duration as well as
severity of the head pain were all significantly reduced at the third and sixth cycles of E2
V/DNG compared with baseline [25]. In addition, and similar to the findings reported by
Macias et al. [24], a significantly lower number of acute abortive analgesics were reported at
cycle six (4.7 ±1.1–2.9 ±0.6, P <0.001) [25].
Overall, these studies demonstrate that sex hormones, both endogenous and exogenous, can
cause alterations in headache patterns in participants with migraine [24,25]. The avoidance
of large magnitude drops in estrogen may improve MRM or other estrogen withdrawal
migraines.
In addition to the pain of migraine, aura has also been demonstrated to vary with estrogen
levels, being more prevalent with high estrogen concentrations and absent in the low
estrogen environment of MRM [26▪▪]. And of more concern, in some studies, migraine’s
increased stroke risk parallels the frequency of aura [32–34]. Calhoun et al. [26▪▪] conducted
a retrospective, clinic-based case series evaluating 23 women with MwA and MRM, and
observed a reduction in aura frequency after extended cycle dosing of a transvaginal ring
contraceptive. This dosing delivers 15 μg ethinyl estradiol/0.120 mg etonogestrel per 24 h.
Extended cycle use was prescribed to assure inhibition of ovulation with this ultra low-dose
CHC, thereby creating an estrogen environment lower than the native menstrual cycle.
Median aura frequency was reduced from 3.23 to 0.23 after treatment (P <0.0005).
Investigators found significantly improved MwA (Z = −4.58, P <0.0005) as well as MRM
(headache eliminated in 91.3% of the evaluable individuals) after treatment [26▪▪].
Genetic studies
Although the above studies focused on the pain and associated symptoms of migraine (i.e.
aura) in those with different hormonal states, one recent study evaluated the genetic
association between estrogen receptor and migraine. Rodriguez-Acevedo et al. [35] recently
evaluated the genetics of the Norfolk Island population, an isolated population with high
levels of consanguineous unions and a relatively homogenous lifestyle, as well as a high
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migraine prevalence. Serum studies and questionnaires were collected from 600 individuals,
and 76 participants with migraine were identified. As previous studies have mapped genes
associated with migraine risk in this population [36], Rodriguez-Acevedo et al. [35]
identified an association with migraine in at least 10 markers of the estrogen receptor 1
gene. Together with recent data revealing substantial heritability in the circulating levels of
sex hormones in adult men [37], these data add complexity to the contribution of estrogen in
the heritability of migraine in certain populations.
THERAPEUTIC CONSIDERATIONS AND FUTURE DIRECTIONS
Although accumulating evidence supports a role for sex hormones in headache, and
particularly migraine, much about the specific mechanisms of how sex hormones affect
migraine remains unknown. As estrogen can extend its impact in a variety of systems, its
role in headache is likely multifactorial, including direct cellular and genetic modifications
in the CNS, as well as potentially as a result of its effect on mood and pain perception
[13,38,39]. Furthermore, the relationship between various sex hormones (i.e. estrogens and
testosterone) is complex, and future studies focusing on the association between these sex
hormones and headache must take into account these interactions.
In addition to pain, migraine aura is affected by sex hormones. Although human studies
have demonstrated a reduction of aura with extreme low-dose CHC [31], experts stress the
importance of inhibition of ovulation as a critical precursor to reduction of aura (so that the
ultra-low doses of these new regimens do not simply augment the endogenous fluctuating
hormone levels). As many women are denied therapy with CHCs, in part because of
published guidelines from the American Congress of Obstetricians and Gynecologists
(ACOG) that recommend against their use in migraine with aura, as well as the lack of
formal statement or guidelines from the International and American Headache Societies,
Calhoun et al.’s recent study demonstrating decreased aura frequency with one of the new
ultra-low-dose regimens may: point to more individualized treatment plans; stimulate larger,
confirmatory trials to establish the safety of CHC use in MwA; and open discussions
between the American and International Headache Societies and ACOG on revisions of
ACOG’s published guidelines.
CONCLUSION
Current literature has consistently demonstrated that headache, in particular migraine, is
more prevalent in women as compared with men, specifically during reproductive years.
Recent studies have found differences in headache characteristics, CNS anatomy as well as
functional activation by fMRI between the sexes in migraine patients. Although the cause
underlying these differences is likely multi-factorial, considerable evidence supports an
important role for sex hormones. Recent studies continue to support that MRM is
precipitated by drops in estrogen concentrations, and minimizing this decline may prevent
these headaches. Limited data also suggest that specific regimens of CHC use in MRM and
MwA may decrease both headache frequency and aura.
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The role of female sex hormone in migraine is continuing to unfold. Future research to
firmly establish the role of CHC and HRT in those with migraine, including those with aura,
is still needed. Additionally, studies with particular focus on delineating the role and
complex relationships between different sex hormones (i.e. estrogen, progesterone/progestin
and testosterone) in headache would be of particular interest. Although translational and
basic science studies have advanced our understanding of the mechanisms of sex hormones,
many questions remain, and our understanding of this topic continues to evolve.
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• Although one of the most common neurological disorders in both women and
men, migraine is 2–3 times more prevalent in women as compared with men.
• Migraine is most prevalent in those of reproductive age.
• Anatomical and brain functional reactivity differences exist between female and
male migraineurs.
• Although steady or increasing levels of estrogen may reduce the risk of migraine
(i.e. pregnancy and menopause), acute migraine attacks may be triggered by
significant drops in estrogen levels.
• Reducing the magnitude of decline in estrogen concentrations in female
migraineurs of reproductive age prevents MRM and reduces MwA attack
frequency.
Chai et al. Page 12























Relative fluctuations of estradiol and progesterone in the human menstrual cycle and rats
estrous cycle. Adapted with permission from Figure 3 of [20].
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